Eisbach Bio
About:
Eisbach Bio is a biotechnology company that creates new drugs that target molecular vulnerabilities in cancer genomes.
Website: https://www.eisbach.bio
Top Investors: Pinto Ventures, Cancer Focus Fund
Description:
Eisbach Bio is a biotechnology company that creates new drugs that target molecular vulnerabilities in cancer genomes. Screening and cellular platforms are yielding first-in-class inhibitors to directly target the key vulnerability found in genetically defined tumors. It is founded in 2019 and is based in Martinsried, Bavaria.
Total Funding Amount:
$4.5M
Estimated Revenue Range:
Less than $1M
Headquarters Location:
Munich, Bayern, Germany
Founded Date:
2019-01-01
Founders:
Adrian Schomburg, Andreas Ladurner
Number of Employees:
11-50
Last Funding Date:
2024-03-21
IPO Status:
Private
Industries:
© 2025 bioDAO.ai